Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome
“The receipt of Orphan Drug Designation in the treatment of LGS represents another significant milestone for our ZX008 development program,” said
Under the U.S. Orphan Drug Act,
For more information, visit www.zogenix.com.
Andrew McDonaldFounding Partner, LifeSci Advisors LLC646-597-6987 | Andrew@lifesciadvisors.com